Christopher Graybill

Christopher Graybill, PhD has extensive experience in the pharmaceutical and clinical research industry. Christopher currently serves as the Sr. Director of Medical Writing at Kiniksa Pharmaceuticals since March 2022. Prior to this, they worked at ARCA biopharma as the VP of Clinical Development from May 2021 to February 2022.

From 2015 to 2021, Dr. Graybill held various positions at Terumo BCT including Senior Manager of Global Clinical Affairs, Manager of Clinical Research, and Manager of Scientific/Clinical Medical Writing.

Before Terumo BCT, they worked as the Manager of Medical Communications at DaVita Clinical Research from June 2012 to February 2015. Additionally, they had experience as a Senior Medical Writer at PRA International from March 2011 to June 2012.

Dr. Graybill also has academic experience as an Affiliate Faculty at Colorado Christian University from August 2009 to January 2012, where they developed and taught medical science courses.

At Gilead Sciences (formerly Myogen, Inc.), they served as a Clinical Research Scientist from March 2006 to January 2010. During this time, they were involved in clinical study design, conduct, and data analysis for cardiovascular compounds.

Dr. Graybill began their career as a Research Scientist at the University of Massachusetts Medical School, conducting research on the molecular physiology of diabetes mellitus within the GLUT family of integral membrane proteins.

Overall, their professional experience spans across various roles in medical writing, clinical development, clinical research, and academia.

Christopher Graybill, PhD, obtained their Bachelor of Science degree in Biochemistry from Susquehanna University, where they studied from 1991 to 1995. Christopher then pursued a PhD in Biochemistry and Molecular Pharmacology at UMass Chan Medical School from 1998 to 2005.